Conversely, DLL4/NICD activation by olmesartan, an angiotensin II receptor blocker, attenuated transverse aortic constriction-induced cardiac remodeling in mice [27] and monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy in rats [28]. This evidence concerns the gene DLL4 and pulmonary hypertension.